TV-1106

DRUG4 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc., Teva Pharmaceutical Industries, Ltd.

Conditions

Growth Hormone DeficiencyGrowth Hormone-Deficiency

Phase 2

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

CompletedNCT01811576

Teva Branded Pharmaceutical Products R&D, Inc.Growth Hormone Deficiency

Start: 2013-03-31End: 2013-08-05Updated: 2021-12-10

A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children

TerminatedNCT02092077

Teva Pharmaceutical Industries, Ltd.Growth Hormone-Deficiency

Start: 2014-04-30End: 2016-08-31Updated: 2021-11-09

Phase 3

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

TerminatedNCT02410356

Teva Branded Pharmaceutical Products R&D, Inc.Growth Hormone Deficiency

Start: 2015-04-30End: 2016-04-30Updated: 2021-12-10

Study of TV-1106 in Growth Hormone-Deficient Adults

TerminatedNCT02410343

Teva Branded Pharmaceutical Products R&D, Inc.Growth Hormone Deficiency

Start: 2015-04-30End: 2015-12-31Updated: 2022-01-24